^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Kidney Cancer

Related cancers:
No biomarker
Renal Cell Carcinoma
pembrolizumab
Sensitive
:
A1
Merck (MSD) Press Release - 6 days - (New A1)
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab
Sensitive
:
A2
PMLive - 1 week - (New A2)
CD27 overexpression
Clear Cell Renal Cell Carcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 3 weeks - (New C3)
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive
:
A1
PD-L1 expression
Renal Cell Carcinoma
avelumab + axitinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
avelumab + axitinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
sorafenib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
tivozanib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
temsirolimus
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
sunitinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
everolimus + lenvatinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
everolimus
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
bevacizumab + pegylated interferon α -2a
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
cabozantinib tablet
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
pembrolizumab + lenvatinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
nivolumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
axitinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
pazopanib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
aldesleukin
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
bevacizumab-maly
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
VHL mutation
Renal Cell Carcinoma
belzutifan
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
bevacizumab-adcd
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
bevacizumab
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
bevacizumab + pegylated interferon α -2a
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
avelumab + axitinib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive
:
A2
No biomarker
Renal Cell Carcinoma
bevacizumab + erlotinib
Sensitive
:
A2
No biomarker
Renal Cell Carcinoma
erlotinib
Sensitive
:
A2